Company intelligence / Profile preview

OncoSil Medical

Macquarie Park, NSW, Australiaoncosil.com ↗

Ownership: Private
Development stage: Commercial

Overview

OncoSil™ has demonstrated positive results in multiple clinical studies for locally advanced unresectable pancreatic cancer. In the PanCO study, more than 90% of patients achieved local disease control at 16 weeks and median survival was extended to approximately 15–16 months when used with chemotherapy. Up to one-third of previously inoperable tumors became potentially resectable after treatment.

Therapeutic areas: Oncology
Modalities: DeviceRadiopharmaceutical (Phosphorous 32 microparticles)Brachytherapy device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

OncoSil

Commercial

Indications: Locally advanced unresectable pancreatic cancer

Partnerships

Distribution partners (Europe, Australia, NZ)

Beyond the preview

Go deeper on OncoSil Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoSil Medical.

Explore the full profile